NCT02583451View on ClinicalTrials.gov

Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
Healthy Participants
Interventions
DRUG

Placebo tablet matching lemborexant

Tablet form taken orally at bedtime.

DRUG

Placebo tablet matching zopiclone

Tablet form taken orally at bedtime.

DRUG

Zopiclone 7.5 mg

7.5 mg tablet taken orally at bedtime.

DRUG

Lemborexant 2.5 mg

2.5 tablet taken orally at bedtime.

DRUG

Lemborexant 5 mg

5 mg tablet taken orally at bedtime.

DRUG

Lemborexant 10 mg

10 mg tablet taken orally at bedtime.

Trial Locations (1)

6229 GS

Maastricht University, Maastricht

All Listed Sponsors
collaborator

Purdue Pharma LP

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT02583451 - Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects | Biotech Hunter | Biotech Hunter